Genentech's Tiragolumab/Tecentriq Fails On Progression Free Survival In PD-L1-High Metastatic Lung Cancer

Genentech, a unit of Roche Holdings AG RHHBY, announced results from its Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab in PD-L1-high locally advanced or metastatic non-small cell lung cancer (NSCLC).
The trial evaluated tiragolumab plus Tecentriq (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment in 534 NSCLC patients.
The study did not meet its co-primary endpoint of progression-free survival.
At this first analysis, the other co-primary endpoint of overall survival was immature, and the study will continue until the next planned analysis.
Also See: Roche's Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial.
A numerical improvement was observed in both co-primary endpoints.
Data suggest that tiragolumab plus Tecentriq was well-tolerated, and no new safety signals were identified when adding tiragolumab.
Tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc region. It selectively binds to TIGIT, a novel inhibitory immune checkpoint, which suppresses the immune response to cancer.